These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1878586)

  • 1. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
    Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire EA; Innig G; Maschmeyer G; Ludwig WD
    Blood; 1991 Sep; 78(5):1190-7. PubMed ID: 1878586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
    Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
    Rowe JM; Andersen JW; Mazza JJ; Bennett JM; Paietta E; Hayes FA; Oette D; Cassileth PA; Stadtmauer EA; Wiernik PH
    Blood; 1995 Jul; 86(2):457-62. PubMed ID: 7605984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
    Estey E; Thall PF; Kantarjian H; O'Brien S; Koller CA; Beran M; Gutterman J; Deisseroth A; Keating M
    Blood; 1992 May; 79(9):2246-55. PubMed ID: 1571541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
    Bettelheim P; Valent P; Andreeff M; Tafuri A; Haimi J; Gorischek C; Muhm M; Sillaber C; Haas O; Vieder L
    Blood; 1991 Feb; 77(4):700-11. PubMed ID: 1993213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
    Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
    Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
    J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
    Löfgren C; Paul C; Aström M; Hast R; Hedenius M; Lerner R; Liliemark J; Nilsson I; Rödjer S; Simonsson B; Stockelberg D; Tidefelt U; Björkholm M
    Br J Haematol; 2004 Feb; 124(4):474-80. PubMed ID: 14984497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
    Witz F; Sadoun A; Perrin MC; Berthou C; Brière J; Cahn JY; Lioure B; Witz B; François S; Desablens B; Pignon B; Le Prisé PY; Audhuy B; Caillot D; Casassus P; Delain M; Christian B; Tellier Z; Polin V; Hurteloup P; Harousseau JL
    Blood; 1998 Apr; 91(8):2722-30. PubMed ID: 9531581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human GM-CSF following chemotherapy in high-risk AML.
    Buechner T; Hiddemann W; Koenigsmann M; Zuehlsdorf M; Woermann B; Boeckmann A; Aguion Freire E; Innig G; Maschmeyer G; Ludwig WD
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():131-4. PubMed ID: 2202465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
    Löwenberg B; Suciu S; Archimbaud E; Ossenkoppele G; Verhoef GE; Vellenga E; Wijermans P; Berneman Z; Dekker AW; Stryckmans P; Schouten H; Jehn U; Muus P; Sonneveld P; Dardenne M; Zittoun R
    Blood; 1997 Oct; 90(8):2952-61. PubMed ID: 9376575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
    Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP
    Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
    Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
    Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies.
    Zimmer BM; Berdel WE; Ludwig WD; Notter M; Reufi B; Thiel E
    Leuk Res; 1993 Mar; 17(3):277-83. PubMed ID: 8450676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
    Kalaycio M; Pohlman B; Elson P; Lichtin A; Hussein M; Tripp B; Andresen S
    Am J Clin Oncol; 2001 Feb; 24(1):58-63. PubMed ID: 11232951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
    Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
    Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts.
    Valent P; Sillaber C; Geissler K; Andreeff M; Tafuri A; Vieder L; Schulz G; Lechner K; Bettelheim P
    Med Pediatr Oncol Suppl; 1992; 2():18-22. PubMed ID: 1306881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.